Catalyst Pharmaceuticals to Present at JPMorgan’s Prestigious Healthcare Conference 2025

Catalyst Pharmaceuticals to Present ‌at Prestigious J.P. ‌Morgan Healthcare Conference

San Francisco, CA ⁤- Catalyst Pharmaceuticals ⁣(NASDAQ: CPRX), a leading biopharmaceutical company focused on ‌developing innovative treatments for rare and debilitating diseases,⁣ announced ‌today its participation in the highly ‍anticipated 43rd ‌Annual J.P.Morgan Healthcare Conference.Richard J. Daly, President and CEO ⁤of Catalyst Pharmaceuticals, will deliver ⁣a presentation highlighting the ⁢company’s recent advancements and ‍future prospects‍ on Thursday, January 16, 2025, ⁤at 10:30 am‌ PST.

The ⁣presentation will be‍ accessible to the public via live webcast through the Investors section of the Catalyst Pharmaceuticals ⁤website. A replay will ​be available for‍ a minimum of 30 days following the event, ⁤providing investors and interested parties with ​ample opportunity to ⁤access⁤ the information.

“We are excited to participate in this prestigious conference and share our progress with‍ the investment community,” said Daly. “The ⁣J.P. Morgan Healthcare Conference provides an⁣ invaluable platform​ to showcase our commitment to developing life-changing therapies for patients with unmet medical needs.”

Catalyst Pharmaceuticals has a ⁤strong ‍track record⁢ of success in bringing novel treatments to market,and the company’s presentation ‍at the J.P. Morgan Healthcare Conference is expected ​to generate meaningful interest among investors‍ and industry stakeholders.

Catalyst pharmaceuticals to Present ⁤at prestigious⁤ J.P. Morgan Healthcare Conference

Miami,FL ⁣ – Catalyst ​Pharmaceuticals,Inc.(NASDAQ: CPRX),‍ a biopharmaceutical company ⁣focused on⁣ developing and commercializing​ therapies for⁢ rare and debilitating diseases, announced today its ⁤participation in the highly anticipated 43rd Annual J.P. ‌Morgan Healthcare Conference.​

Richard J. Daly,President and CEO of Catalyst‍ Pharmaceuticals,will deliver a presentation on Thursday,January 16,2025,at 10:30​ AM PST in ⁢San ⁢Francisco.

“We are excited to share our progress ⁤and vision‌ for⁢ the future ​with the investment community at this premier⁣ healthcare event,” said Daly. “The J.P. Morgan‍ Healthcare Conference provides an invaluable platform to ⁤showcase our commitment to developing innovative treatments for patients‌ in need.”

The presentation will be accessible via webcast‍ on the⁢ Investor relations⁤ section of the catalyst Pharmaceuticals website. A‍ replay will be available for at least 30 days following the event.

The J.P.Morgan Healthcare Conference is a‌ leading industry event that brings⁤ together⁣ global​ leaders in the healthcare sector, including investors, pharmaceutical executives, and⁢ researchers. Catalyst’s⁤ participation underscores the company’s dedication to advancing its ‍pipeline of promising therapies‍ and its‍ commitment to openness ​with⁤ investors.

Catalyst Pharmaceuticals to present at Prestigious J.P. Morgan Healthcare Conference

CORAL ⁣GABLES, Fla., Dec. 16, 2024 – Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX),a biopharmaceutical company dedicated to ⁤developing treatments for rare and⁤ challenging diseases,announced today ⁢that President and CEO Richard J. daly will ‌present at the 43rd Annual ⁤J.P. Morgan Healthcare Conference.​ The conference, a major event in the ⁤biotech and⁤ pharmaceutical industry, ‍will take place January ​13-16, 2025, in San Francisco, CA.

This prominent platform offers Catalyst a valuable opportunity to showcase ⁤its latest⁤ advancements in ‌novel ​medications and therapies.

Presentation Details:

Date: Thursday,January 16,2025
Time: 10:30 am PST
* Webcast: Link to Webcast

The webcast ⁣will also be accessible on the Investors section of the Catalyst Pharmaceuticals website.

This presentation⁢ marks a significant moment for Catalyst as⁤ it continues to make strides in its⁤ mission ⁢to ⁢improve the lives of patients with​ rare diseases.

Catalyst Pharmaceuticals to Present at‍ Prestigious J.P. Morgan Healthcare ​Conference

Coral Gables,⁣ FL ⁣–⁣ December 18, 2024 – Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), a leading biopharmaceutical⁤ company⁢ dedicated to developing treatments for rare diseases, announced today​ that it will present at the renowned J.P. Morgan Healthcare Conference in San Francisco.

The presentation, scheduled for Thursday, January ⁣16, 2025, at 10:30​ am PST, will ‌provide an update on ‌Catalyst’s progress and future plans. investors and other interested parties can access a live webcast of the presentation ‌through the “Investors” ​section of the Catalyst ⁣Pharmaceuticals website at www.catalystpharma.com. A replay will be available for at least 30 days following the event.

“We are excited to⁣ share our latest advancements and vision for the⁤ future with the investment community‌ at this prominent healthcare conference,” said [Insert Name and Title of Catalyst Pharmaceuticals Executive]. “Catalyst remains committed⁤ to delivering innovative therapies that improve the lives of patients with rare⁣ diseases, and we look forward to discussing our ongoing efforts ‌in this importent area.”

About ⁣Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is ⁢a ⁤biopharmaceutical company focused on⁢ developing and commercializing therapies for rare diseases. With a proven ‌track record of bringing life-changing treatments to market, Catalyst prioritizes patient access through comprehensive ⁢support services. Headquartered in​ Coral Gables, Florida, Catalyst⁢ was recently recognized as one of North America’s Fastest-Growing ​Companies on the ⁣2024 Deloitte Technology Fast 500™ ‌List.

For more ‌information,⁣ please visit www.catalystpharma.com.

Forward-Looking Statements

This ​press ‍release⁤ contains forward-looking statements within the meaning ‌of the Private Securities Litigation Reform‍ Act of‍ 1995. These statements involve known and unknown risks and uncertainties ‌that ⁢may cause Catalyst’s actual results to differ materially​ from those expressed or implied ⁢in such statements. Factors that could cause ​or contribute to such differences include, but ‍are not‍ limited to, ⁤those discussed ​in⁣ Catalyst’s Annual report on Form 10-K for ⁢the fiscal year 2023 and its other filings with the ​U.S.Securities and Exchange Commission. Catalyst does not undertake any obligation to ⁣update or revise any forward-looking statements, whether as a‍ result⁣ of new information, future events or otherwise.

Catalyst Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

Coral Gables, FL ‍ – catalyst pharmaceuticals, Inc. (CPRX), ‍a biopharmaceutical company focused⁢ on developing treatments for rare ⁢diseases,⁣ announced today⁤ that it will present at⁢ the 41st Annual⁢ J.P. Morgan ​Healthcare Conference. ‌

The presentation will take place ⁣on [Insert Date] at [Insert Time] ⁣ PST. ​Investors ⁣interested⁤ in learning more about Catalyst’s pipeline and progress ⁣can⁣ access the live webcast through the⁤ Investors ​section of the‌ company’s website, ​www.catalystpharma.com.‍ A replay of the presentation ​will​ be‍ available on the ​website for at least 30 days following the event.Catalyst Pharmaceuticals is dedicated to improving‌ the lives of​ patients with⁤ rare and ⁣debilitating diseases. The company’s focus on⁤ in-licensing, ⁣developing, and commercializing novel⁤ medicines makes it a key⁤ player in the field of rare disease therapeutics.

Catalyst Pharmaceuticals⁢ to⁣ Shine Spotlight ⁣on Rare Disease Treatments at J.P. Morgan healthcare Conference

San Francisco, CA, December 16, 2024 – Excitement is ​building for‌ Catalyst Pharmaceuticals (NASDAQ: ⁤CPRX), a⁢ leading biopharmaceutical company ‌specializing in innovative treatments for rare ⁢and debilitating diseases, as they prepare to take center stage at⁤ the prestigious 43rd Annual J.P. Morgan Healthcare Conference.

We spoke with Dr. [Expert name], a respected industry analyst with [Expert Credentials] about Catalyst’s participation and⁢ the potential impact of this high-profile event.

NewsDirect: Catalyst Pharma has positioned itself⁣ as a key player in the field of ‍rare diseases. What​ makes‌ their participation in the⁤ J.P. Morgan Healthcare Conference so significant?

Dr. [Expert Name]: This conference is a gold‍ standard‍ in the healthcare industry. It attracts a who’s who‍ of ‍investors, researchers,⁤ and industry leaders. For ⁣Catalyst, this is a prime prospect to not only‌ showcase their exciting pipeline‍ of treatments but also​ build relationships and garner crucial attention from the investment community.

NewsDirect: What specific advancements⁢ might Catalyst highlight during their ​presentation⁣ on January 16th?

Dr.[Expert Name]: We can expect Catalyst to focus ‌on​ their recent progress in developing novel therapies for [Mention specific disease areas Catalyst focuses on]. Their presentation​ will likely delve into ⁣clinical​ trial​ results, new research findings, and their strategic plans‌ for bringing these⁤ groundbreaking treatments to market.

NewsDirect: What message do​ you⁤ anticipate Catalyst ⁣will convey to investors and industry ⁣stakeholders?

Dr. ​ [Expert Name]: I anticipate a strong emphasis on⁤ Catalyst’s ⁣commitment to improving the lives⁣ of ​patients with rare diseases. They ‌will ‌likely highlight their⁤ dedication to⁣ rigorous scientific research,their compassionate approach to patient care,and ⁤their vision for becoming a ⁣global leader in this vital therapeutic area.

NewsDirect: How might Catalyst’s presentation at ‌the J.P. Morgan Healthcare Conference impact their future?

Dr. [Expert Name]: A compelling presentation can considerably boost ⁣investor ‌confidence and ‌generate⁣ excitement around Catalyst’s‍ future prospects. This, in turn, could lead to increased funding opportunities, stronger partnerships, and ultimately, a faster ​path⁣ to bringing life-changing treatments to patients⁣ who desperately need them.

The Takeaway:

Catalyst Pharmaceuticals’ participation in the J.P. Morgan Healthcare Conference is a testament to their leading role in the rare​ disease space. Their ⁣presentation promises to shed light on important advancements and ‌reinforce their dedication ‌to developing innovative therapies. the ⁣entire​ healthcare community will be watching‌ closely as Catalyst ‍takes‌ this ​crucial step toward achieving their ambitious goals.